The Comparison of Clinical and Laboratory Indexes for Diagnosis of Vaginal Atrophy in Postmenopausal Women

Document Type : Original Article


1 Assistant Professor of Midwifery, School of Nursing and Midwifery, Mashhad University of Medical Sciences, Mashhad, Iran.

2 M.Sc. Student of Midwifery, School of Nursing and Midwifery, Mashhad University of Medical Sciences, Mashhad, Iran.

3 Associate Professor, Department of Obstetrics and Gynecology, Ovulation Dysfunction Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

4 Professor, Department of Pharmaceutics, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.

5 Professor, Department of Pathology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

6 Professor, Department of Community Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.


Introduction: Vaginal atrophy (VA) causes by estrogen deficiency and occurs in postmenopausal women. Today, clinical signs and symptoms are used for detection of vaginal atrophy. Laboratory techniques are other methods that can be used. The aim of this study was to compare the clinical and laboratory indexes for the diagnosis of vaginal atrophy in postmenopausal women.
Methods: This correlational study was conducted in 2013 on 100 postmenopausal women who had attended tohealth centers number 1 and 3 and gynecology clinic of Ghaem hospital of Mashhad, Iran. Data were gathered by a demographic information form and observation and examination of vaginal atrophy form. Data were analyzed by SPSS software version 11.5, descriptive statistics and Spearman correlation coefficients. P value less than 0.05 was considered significant.
Results: There was not significant correlation between vaginal dryness (p=0.08), elasticity of vagina (p=0.26), color of vagina (p=0.14), rugae (p=0.68) and vaginal petechiae (p=0.52) with vaginal maturation value but there was positive correlation between petechiae (p=0.00) and color of vagina (p=0.03) with vaginal PH.
Conclusion: There are differences between the clinical and laboratory diagnosis of vaginal atrophy. Recognition of vaginal atrophy based on clinical signs and symptoms is not enough and according to the adverse effects of hormone therapy, it is recommended that definitive diagnosis of vaginal atrophy should be made based on laboratory evaluation.


  1. Morali G, Polatti F, Metelitsa EN, Mascarucci P, Magnani P, Marre GB. Open, non-controlled clinical studies to assess the efficacy and safety of a medical device in form of del topically and intravaginally used in postmenopausal women with genital atrophy. Arzneimitteforschung 2006;56(3):230-8 .
  2. Cotreau MM, Chennathukuzhi VM, Harris HA, Han L, Dorner AJ, Apseloff G, et al. A study of 17betaestradiol-regulated genes in the vagina of postmenopausal women with vaginal atrophy. Maturitas 2007 Dec 20;58(4):366-76.
  3. Chism LA. Overcoming resistance and barriers to the use of local estrogen therapy for the treatment of vaginal atrophy. Int J Womens Health 2012;4:551-7.
  4. Hacker NF, Moor JG, Gambone JC. Essentials of obstetrics and gynecology. 4th ed. Philadelphia:Elsevier Saunders;2004.
  5. Labrie F, Cusan L, Gomez G, Cote I, Berube R, Belanger P, et al. Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women. J Steroid Biochem Mol Biol 2008 Sep;111(3-5):178- 94.
  6. Raymundo N, Yu-cheng B, Zi-yan H, Lai CH, Leung K, Subramaniam R, et al. Treatment of atrophic vaginitis with topical conjugated equine estrogens in postmenopausal Asian women. Climacteric 2004 Sep;7(3):312-8.
  7. D'Hooghe TM. Endometriosis. In: Berek JS, Berek DL. Berek and Novak's gynecology. 14th ed. Philadelphia:Lippincott Williams & Wilkins;2012:505-56.
  8. Sturdee DW, Panay N. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 2010 Dec;13(6):509-22.
  9. Le Donne M, Caruso C, Mancuso A, Costa C, Iemmo R, Pizzimenti G, et al. The effect of vaginally administered genistein in comparison with hyaluronic acid on atrophic epithelium in postmenopause. Arch Gynecol Obstet 2011 Jun;283(6):1319-23.
  10. Marxa P, Schade G, Wilbourn S, Blank S, Moyer DL, Nett R. Low-dose (0.3 mg) synthetic conjugated estrogens A is effective for managing atrophic vaginitis. Maturitas 2004 Jan 20;47(1):47-54.
  11. Speroff L, Fritz MA. Clinical gynecologic endocrinology and infertility. 7th ed. Philadelphia:Lippincott Williams & Wilkins;2005.552-99.
  12. Gharekhani P, Sadatiyan A. [Women’s diseases]. Tehran:Noordanesh Publication;2000. [in Persian].]
  13. Panjari M, Davis SR. Vaginal DHEA to treat menopause related atrophy: a review of the evidence. Maturitas 2011 Sep;70(1):22-5.
  14. Palacios S. Managing urogenital atrophy. Maturitas 2009 Aug 20;63(4):315-8.
  15. Bachmann G. Urogenital ageing: an old problem newly recognized. Maturitas 1995 Dec;22 Suppl:S1-S5.
  16. Parsons A, Merritt D, Rosen A, Heath H 3rd, Siddhanti S, Plouffe L Jr. Effect of raloxifene on the response to conjugated estrogen vaginal cream or nonhormonal moisturizers in postmenopausal vaginal atrophy. Obstet Gynecol 2003 Feb;101(2):346-52.
  17. Johnston SL, Farrell SA, Bouchard C, Beckerson LA, Comeau M, Lefebvre G, et al. The detection and management of vaginal atrophy. J Obstet Gynecol Can 2004 May;26(5):503-15.
  18. Castelo-Branco C, Cancelo MJ, Villero J, Nohales F, Juli MD. Management of post-menopausal vaginal atrophy and atrophic vaginitis. Maturitas 2005 Nov 15;52 Suppl 1:S46-52.
  19. Carranza-Lira S, Fragoso-Dıaz N, MacGregor-Gooch AL, Garduno-Hernandez MP, Rıos-Calderon K, Aparicio H. Vaginal dryness assessment in postmenopausal women using pH test strip. Maturitas 2003 May 30;45(1):55- 8.
  20. Yörük P, Uygur M, Erenus M, Eren F. The role of vaginal maturation value assessment in prediction of vaginal pH, serum FSH and E2 levels. Marmara Med J 2006;19(2):52-7.
  21. Maloney C, Oliver ML. Effect of local conjugated estrogens on vaginal pH in elderly women. J Am Med Dir Assoc 2001 Mar-Apr;2(2):51-5.
  22. Esmaeilpour N, Mirboluk F, Asgharnia M, Nasr S. [Correlation between vaginal pH and serum follicle stimulating hormone in Menopausal women] [Article in Persian]. Iran J Obstet Gynecol Infertil 2009;11(3):25- 30.
  23. Vahidroodsari F, Ayati S,Yousefi Z, Saeed S. Comparing Serum Follicle-Stimulating Hormone (FSH) Level with Vaginal PH in Women with Menopausal Symptoms. Oman Med J 2010 Jan;25(1):13-6.
  24. Lynch C. Vaginal estrogen therapy for the treatment of atrophic vaginitis. J Womens Health (Larchmt) 2009 Oct;18(10):1595-606.
  25. Brizzolara S, Killeen J, Severino R. Vaginal pH and parabasal cells in postmenopausal women. Obstet Gynecol 1999 Nov;94(5 Pt 1):700-3.
  26. Stone SC, Mickal A, Rye PH. Postmenopausal symptomatology, maturation index, and plasma estrogen levels. Obstet Gynecol 1975 Jun;45(6):525-7.
  27. Miller KL, Versi E, Resnick NM. Geriatric gynecology and agin. In: Rayan KJ, Berkowitz RS, Dunaif A. Kistner's gynecology & women's health. 7th ed. St. Louis:Mosby;1999:610-38.
  28. Nilsson K, Risberg B, Heimer G. The vaginal epithelium in the postmenopause--cytology, histology and pH as methods of assessment. Maturitas 1995 Jan;21(1):51-6.
  29. Notelovitz M. Estrogen therapy in the management of problems associated with urogenital ageing: a simple diagnostic test and the effect of the route of hormone administration. Maturitas 1995 Dec;22 Suppl:S31-3.
  30. Shahraz S, Ghaziyani T. Iranpharma. Tehran:Teymurzade;2008.
  31. Capewell AE, McInteri MA , Elton RA. Post-menopausal atrophy in elderly women: is a vaginal smear necessary for diagnosis? 1992 Mar;21(2):117-20.
  32. Davila GW, Singh A, Karapanagiotou I, Woodhouse S, Huber K, Zimberg S, et al. Are women with urogenital atrophy symptomatic? Am J Obstet Gynecol 2003 Feb;188(2):382-8.
  33. Greendale GA, Zibecchi L, Petersen L, Ouslandert JG, Ganz PA. Development and validation of aphysical examination scale vaginal atrophy and inflammation to assess vaginal atrophy and inflammation. Climacteric 1999 Sep;2(3):197-204.